

# Enterocolitis - Pipeline Review, H2 2019

<https://marketpublishers.com/r/EA1C90BB84DEN.html>

Date: December 2019

Pages: 54

Price: US\$ 2,000.00 (Single User License)

ID: EA1C90BB84DEN

## Abstracts

Enterocolitis - Pipeline Review, H2 2019

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Enterocolitis - Pipeline Review, H2 2019, provides an overview of the Enterocolitis (Gastrointestinal) pipeline landscape.

Enterocolitis is an inflammation of the large and small intestines. Symptoms include fever, abdominal swelling, nausea, diarrhea, rectal bleeding and sluggishness. Causes of enterocolitis include Inflammation of the intestinal tissues, delayed gastric emptying, abdominal wall erythema, apnea, sepsis and cardiovascular collapse. Treatment includes antibiotics.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Enterocolitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Enterocolitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Enterocolitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Enterocolitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III,

Phase II and Preclinical stages are 1, 1 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Enterocolitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Enterocolitis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Enterocolitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Enterocolitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Enterocolitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Enterocolitis (Gastrointestinal)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Enterocolitis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Enterocolitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Enterocolitis - Overview

Enterocolitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Enterocolitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Enterocolitis - Companies Involved in Therapeutics Development

Avexegen Therapeutics Inc

Glycohub Inc

Glycosyn LLC

Infant Bacterial Therapeutics AB

Leadiant Biosciences Inc

Liminal BioSciences Inc

Noveome Biotherapeutics Inc

Plakous Therapeutics Inc

Scioto Biosciences Inc

Synthetic Biologics Inc

Worphmed Srl

Enterocolitis - Drug Profiles

alpha-1 proteinase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-34 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBP-9414 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NRG-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PROTEGO-PD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Necrotizing Enterocolitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-266 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYN-020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Enterocolitis - Dormant Projects

## Enterocolitis - Product Development Milestones

### Featured News & Press Releases

Jul 05, 2019: Infant Bacterial enrolls first patient in NEC study

May 19, 2019: FDA and Infant Bacterial Therapeutics agree on the design of Phase III study

Mar 05, 2019: Infant Bacterial Therapeutics announces first distribution agreement

Nov 21, 2018: The Phase 3 study protocol is modified after IBT's meeting with the FDA

Nov 09, 2018: IBT's Chief Scientific Officer invited to speak at NEC Society Symposium 2019

May 15, 2018: Infant Bacterial Therapeutics: Interim Management Statement, January 1 - March 31, 2018

Mar 05, 2018: Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its Inter-Alpha-Inhibitor-Proteins

Feb 15, 2018: Prometic granted orphan drug designation by FDA for Inter-Alpha-Inhibitor-Proteins for treatment of necrotizing enterocolitis (NEC)

Dec 11, 2017: Infant Bacterial Therapeutics presents data from its Safety and Tolerability Study in premature infants

Nov 23, 2017: Infant Bacterial Therapeutics Interim Management Statement, January 1 - September 29, 2017

Sep 28, 2017: European Medicines Agency adopts a positive opinion on the Paediatric Investigation Plan for IBT's lead product

Sep 11, 2017: Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups

Jan 24, 2017: Last patient enrolled in IBT's Phase 2 study

Nov 21, 2016: Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study

Jun 07, 2016: Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Enterocolitis, H2 2019  
Number of Products under Development by Companies, H2 2019  
Number of Products under Development by Universities/Institutes, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Universities/Institutes, H2 2019  
Number of Products by Stage and Target, H2 2019  
Number of Products by Stage and Mechanism of Action, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Enterocolitis - Pipeline by Avexegen Therapeutics Inc, H2 2019  
Enterocolitis - Pipeline by Glycohub Inc, H2 2019  
Enterocolitis - Pipeline by Glycosyn LLC, H2 2019  
Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB, H2 2019  
Enterocolitis - Pipeline by Leadiant Biosciences Inc, H2 2019  
Enterocolitis - Pipeline by Liminal BioSciences Inc, H2 2019  
Enterocolitis - Pipeline by Noveome Biotherapeutics Inc, H2 2019  
Enterocolitis - Pipeline by Plakous Therapeutics Inc, H2 2019  
Enterocolitis - Pipeline by Scioto Biosciences Inc, H2 2019  
Enterocolitis - Pipeline by Synthetic Biologics Inc, H2 2019  
Enterocolitis - Pipeline by Worphmed Srl, H2 2019  
Enterocolitis - Dormant Projects, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Enterocolitis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

Avexegen Therapeutics Inc

Glycohub Inc

Glycosyn LLC

Infant Bacterial Therapeutics AB

Leadiant Biosciences Inc

Liminal BioSciences Inc

Noveome Biotherapeutics Inc

Plakous Therapeutics Inc

Scioto Biosciences Inc

Synthetic Biologics Inc

Worphmed Srl



## I would like to order

Product name: Enterocolitis - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/EA1C90BB84DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EA1C90BB84DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970